V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1) Peptid
Kurzübersicht für V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1) Peptid (ABIN964063)
Target
Quelle
-
-
Protein-Typ
- Synthetic
-
Hersteller Produkt- Nr.
- 000-000-401
-
Hersteller
- Rockland
-
Verwendungszweck
- AKT Peptide
-
Produktmerkmale
- control peptide, blocking peptide, RAC-PK-alpha, Protein kinase B, PKB, C-AKT, RAC-alpha serine/threonine-protein kinase, Proto-oncogene c-Akt, AKT1, AKT Serine/Threonine Kinase 1, AKT 1 Antibody, AKT-1.
-
Aufreinigung
- Greater than 95% specific peptide
-
Reinheit
- Greater than 95% specific peptide
-
Sterilität
- Sterile filtered
-
-
-
-
Applikationshinweise
- Optional[Flow Cytometry Dilution]: Akt blocking peptide should be used at 1.0 μg per 1.0 μL of antiserum in per assay.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1.0 mg/mL
-
Buffer
-
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Stabilizer: None
Preservative: 0.01 % (w/v) Sodium Azide -
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
-
Haltbarkeit
- 6 months
-
-
- AKT1 (V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1))
-
Hintergrund
-
Synonyms: control peptide, blocking peptide, RAC-PK-alpha, Protein kinase B, PKB, C-AKT, RAC-alpha serine/threonine-protein kinase, Proto-oncogene c-Akt, AKT1, AKT Serine/Threonine Kinase 1, AKT 1 Antibody, AKT-1.
Background: Non-specific binding of an antibody to proteins other than the antigen can sometimes occur. This is usually more common with polyclonal antibodies, but can also occur with monoclonals as well. To determine which band or staining is specific, the AKT immunizing peptide blocking experiment can be performed. Prior to the staining protocol, the anti-AKT antibody is neutralized (incubated with an excess of peptide that corresponds to the epitope recognized by the antibody). The AKT antibody that is bound to the blocking peptide is no longer available to bind to the epitope present in the protein on the Western blot or in the cell. The neutralized antibody is then used side-by-side with the antibody alone, and the results are compared. By comparing the staining from the blocked antibody versus the antibody alone, you can see which staining is specific: this staining will be absent from the Western blot or immunostaining performed with the neutralized antibody.
Target
-
